Health · 1 sources covering this

The future of heart drug research in the wake of study setbacks

What does the failure of two closely watched heart disease medicines mean for the future of drug research in the field? Find out on this week's episode of "The Readout…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
The future of heart drug research in the wake of study setbacks
What does the failure of two closely watched heart disease medicines mean for the future of drug research in the field? Find out on this week's episode of "The Readout…
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/9ad7caa8d5dab3495d90e9b2bce427404d533409"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="The future of heart drug research in the wake of study setbacks"></iframe>

The future of heart drug research in the wake of study setbacks

How 1 sources are covering this

The future of heart drug research in the wake of study setbacks

More from Health

Opinion: New organ donation rules are unfair to families

Brain implant startup pauses trials

STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more

STAT+: Senators introduce bill to curb conflicts of interest on preventive care panel

Reader

Trust & legal

Across the network

How 1 sources are covering this

The future of heart drug research in the wake of study setbacks

More from Health

Opinion: New organ donation rules are unfair to families

Brain implant startup pauses trials

STAT+: Pharmalittle: We&#8217;re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more

STAT+: Senators introduce bill to curb conflicts of interest on preventive care panel

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more